CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0500 (clinicaltrials.gov NCT No: NCT00821249)
Title:A Phase 1/2 Study of ARRY-520 in Patients with Relapsed or Refractory Multiple Myeloma
Principal Investigator:Jatin J. Shah
Treatment Agent:ARRY-520
Study Status:Closed
Study Description:The goal of the Phase I part of this clinical research study is to find the
highest tolerable dose of ARRY-520 when given to patients with multiple myeloma
or plasma cell leukemia who get ARRY-520 alone or ARRY-520 with Neupogen
(filgrastim).

The goal of the Phase II part of this study is to learn if ARRY-520 with or
without dexamethasone can help to control multiple myeloma or plasma cell
leukemia. The safety of this drug will be studied in both parts.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:ARRY-520
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Array Biopharma
Return Visit:Screening; cycle 1 days 1, 2, 3, 4 and 8. Cycle 2: Days 1, 2, 3, 4 and 8. The
patient will return for a follow-up visit 30 days after the last treatment.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults